Skip to main content

The independent medical news service

30-01-2023 | Oncology | News | Article

EMA recommends new indication for darolutamide

Click through to find out more

27-01-2023 | Oncology | News | Article

Guideline for oncogene-addicted metastatic NSCLC issued by ESMO

Click through for the details of these evidence-based recommendations

26-01-2023 | Oncology | News | Article

Adding camrelizumab to chemo prolongs OS of patients with advanced nonsquamous NSCLC

An updated analysis of the CameL trial has shown a significant improvement in overall survival with the addition of camrelizumab to chemotherapy in treatment-naïve Chinese patients with advanced nonsquamous non-small-cell lung cancer.

23-01-2023 | Oncology | News | Article

ESMO releases guideline for metastatic NSCLC without oncogenic drivers

More information about this Clinical Practice Guideline available here

20-01-2023 | Oncology | News | Article

IL-7 genetic variant linked to ICI toxicity

A variant of the interleukin 7 gene is associated with an increased risk of immune-related adverse events in people with cancer receiving immune checkpoint inhibitor therapy, suggests research.

18-01-2023 | Oncology | News | Article

Veliparib addition may improve PFS for metastatic TNBC patients with BRCA-like phenotype

Use of veliparib during cisplatin chemotherapy may help improve progression-free survival in patients with metastatic triple-negative breast cancer displaying biomarker characteristics similar to those seen in BRCA1/2 mutation-positive disease, suggest findings from a phase 2 trial.

17-01-2023 | Oncology | News | Article

CT brain cancer risk quantified for children and young adults

The European EPI-CT study has confirmed there is a linear dose–response relationship between radiation exposure during computed tomography imaging and the risk of malignant brain tumours, in children and young adults.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

16-01-2023 | Oncology | News | Article

Neoadjuvant gemcitabine–cisplatin ‘a viable option’ for high-grade UTUC

A phase 2 trial has demonstrated the promising efficacy and tolerability of neoadjuvant gemcitabine plus split-dose cisplatin in patients with localised high-grade upper tract urothelial carcinoma.

13-01-2023 | Oncology | News | Article

ESMO guideline on VTE prevention, treatment now available

Find out more about the evidence-based recommendations here

12-01-2023 | Oncology | News | Article

CROWN update confirms long-term lorlatinib PFS benefit

Lorlatinib offers a “durable benefit” for the first-line treatment of advanced ALK-positive non-small-cell lung cancer, indicates a 3-year update from the CROWN trial.

Antibodies attacking SARS-CoV-2 virus, the conceptual 3D illustration for COVID-19 treatment, diagnosis and prevention

10-01-2023 | Oncology | Highlight | Article

Antibody testing may identify cancer patients at increased risk of COVID-19 breakthrough infections

A Canadian population-based study has confirmed that people with cancer have an increased risk of breakthrough COVID-19 infection after vaccination, while UK research points to the feasibility of SARS-CoV-2 antibody testing to identify those with the lowest level of vaccine-derived protection.

19-12-2022 | Oncology | News | Article

Obesity may increase irAE risk among nivolumab-treated patients

A pooled analysis of clinical trial data points to a link between obesity and an increased risk for any-grade immune-related adverse events among people receiving nivolumab monotherapy for advanced cancer.

12-12-2022 | Oncology | News | Article

Phase 3 data support add-on capivasertib in people with AI-resistant advanced breast cancer

The addition of the AKT inhibitor capivasertib to fulvestrant significantly prolongs the progression-free survival of people with hormone receptor-positive, HER2-negative advanced breast cancer that is resistant aromatase inhibitors, indicate the results of CAPItello-291.

09-12-2022 | Oncology | News | Article

Encouraging data for neoadjuvant T-DXd in HER2-low early breast cancer

Trastuzumab deruxtecan has demonstrated promising efficacy and tolerability in the neoadjuvant treatment of HER2-low, hormone receptor-positive early breast cancer in the TRIO-US B-12 TALENT trial.

09-12-2022 | Oncology | News | Article

Next-generation oral SERD shows promise in ER-positive, advanced breast cancer

Treatment with the novel oral selective estrogen receptor degrader camizestrant significantly improves progression-free survival versus fulvestrant in patients with pretreated, estrogen receptor-positive, HER2-negative advanced breast cancer, shows a phase 2 study.

08-12-2022 | Oncology | News | Article

monarchE 4-year results show abemaciclib benefit is maintained beyond treatment completion

The 4-year results from monarchE indicate that the invasive disease-free survival gain offered by adjuvant abemaciclib in people with high-risk, hormone receptor-positive, HER2-negative, early breast cancer is maintained even after the 2-year treatment period.

08-12-2022 | Oncology | News | Article

First-line ribociclib plus ET RIGHT Choice for aggressive advanced breast cancer

Ribociclib plus endocrine therapy is associated with a significant progression-free survival benefit relative to combination chemotherapy in treatment-naïve patients with hormone receptor-positive, HER2-negative, advanced breast cancer with aggressive features, suggest trial data.

08-12-2022 | Oncology | News | Article

Neurocognitive caution for intensive CNS-directed treatment of childhood ALL

Children with a new diagnosis of acute lymphoblastic leukaemia who receive intensified central nervous system-directed therapy have an increased risk of neurocognitive deficits, indicates research published in the Journal of Clinical Oncology.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

Box of statins, prescription and a stethoscope

05-12-2022 | Oncology | News | Article

Statins tied to improved survival in men receiving androgen-ablative therapies

Men with advanced prostate cancer may derive a significant survival benefit from the concurrent use of statins alongside androgen-ablative therapies, suggest the Canadian authors of a systematic review and meta-analysis.

02-12-2022 | Rheumatology | News | Article

Anti-SSSCA1 positivity tied to cancer risk in SSc patients

Study findings reported in Rheumatology suggest that anti-SSSCA1 antibodies may warrant further investigation as a biomarker for cancer risk among patients with systemic sclerosis.